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Abstract
Background: There is a lack of high quality, child-centred and effective health information to support
development of self-care practices and expertise in children with acute and long-term conditions. In type 1
diabetes, clinical guidelines indicate that high-quality, child-centred information underpins achievement of optimal
glycaemic control with the aim of minimising acute readmissions and reducing the risk of complications in later
life. This paper describes the development of a range of child-centred diabetes information resources and outlines
the study design and protocol for a randomized controlled trial to evaluate the information resources in routine
practice. The aim of the diabetes information intervention is to improve children and young people’s quality of life
by increasing self-efficacy in managing their type 1 diabetes.
Methods/Design: We used published evidence, undertook qualitative research and consulted with children, young
people and key stakeholders to design and produce a range of child-centred, age-appropriate children’s diabetes
diaries, carbohydrate recording sheets, and assembled child-centred, age-appropriate diabetes information packs
containing published information in a folder that can be personalized by children and young people with pens
and stickers. Resources have been designed for children/young people 6-10; 11-15; and 16-18 years.
To evaluate the information resources, we designed a pragmatic randomized controlled trial to assess the effectiveness,
cost effectiveness, and implementation in routine practice of individually tailored, age-appropriate diabetes diaries and
information packs for children and young people age 6-18years, compared with currently available standard practice.
Children and young people will be stratified by gender, length of time since diagnosis (< 2years and > 2years) and
age (6-10; 11-15; and 16-18 years). The following data will be collected at baseline, 3 and 6 months: PedsQL
(generic, diabetes and parent versions), and EQ-5 D (parent and child); NHS resource use and process data
(questionnaire and interview). Baseline and subsequent HbA1c measurements, blood glucose meter use, readings
and insulin dose will be taken from routine test results and hand-held records when attending routine 3-4 monthly
clinic visits.
The primary outcome measure is diabetes self-efficacy and quality-of-life (Diabetes PedsQL). Secondary outcomes
include: HbA1c, generic quality of life, routinely collected NHS/child-held data, costs, service use, acceptability and
utility.
Trial Registration: ISRCTN17551624.
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The requirement for health information
People of all ages require high quality information pro-
moting health, self-care and medicines management to
help facilitate their engagement in participative models
of health care, and assist them in making choices [1-4].
In the United Kingdom (UK) the National Health Ser-
vice (NHS) Constitution makes clear that patients
require information to engage fully and knowledgably in
decision-making, and be aware of risks and benefits of
treatment options [4].
Policy makers also identify a need for health and
social services providers to increase capacity, confidence
and efficacy of individuals for self-care and to build
social capital in the community [4-10]. The requirement
for prevention, early intervention and support for indivi-
duals for self-care, and promoting wellbeing for the
wider population is a fundamental policy aspiration
[4-10]. However, there is uncertainty about the position-
ing of children, young people and their families within
these models and policies and what practical plans and
processes exist for successful implementation.
Children’s age-appropriate and child-centred health
information is likely to be critical to developing self-care
and wellbeing as children’s autonomy increases with age
[9]. Information needs and informed choice are central
to the Children’s National Service Framework (NSF),
(including a standard on medicines management, and the
Children’s Plan, which make specific reference to the
requirement to provide high-quality, age-appropriate,
child-centred information in varying formats) [9-11].
T h e r ei sh o w e v e rl i t t l er e l i a b l ee v i d e n c ec o n c e r n i n gt h e
effectiveness of different types of provision of health infor-
mation for children and young people. There is even less
evidence about types and formats of information which
could empower children and young people to make deci-
sions and choices, where appropriate, about aspects of
their care [12].
Progress has been made on a UK strategy for service
delivery and organisation of medicines for children and
young people to facilitate not only a measurable increase
in appropriately labelled and formulated medicines and
conduct of trials, but also information for prescribers,
carers and children [9]. One outcome is the setting-up
of the Medicines for Children Research Network
(MCRN), [13] which is supporting the EPIC project and
linked foundation study the Information Matters Project
(IMP), funded by the National Institute for Health
Research: Service Delivery and Organisation [14,15].
Broad policy background
The need for child-centred, age-appropriate information
on medicines specifically, and self-care management in
general, is highlighted when viewed against the broader
NHS public health policy context. Children’sh e a l t hp o l -
icy is centred on the notion of ‘family-centred’ care with
family members providing a large proportion of care,
and with children taking on more responsibility for their
healthcare as they gain autonomy. The Children’sN S F
model of children’s acute and chronic disease manage-
ment focuses on educating children/young people in
age-appropriate ways to deliver aspects of their own
healthcare, and specifically identifies parents as experts
[4]. The shift in focus to homecare and community set-
tings requires complex arrangements for medicines and
treatments and greater support for parents and chil-
dren/young people who are administering increasingly
complex medicines (eg insulin pumps), and treatment
regimes, and who are recommended to adapt their life-
styles to optimise health [9]. Information on self-admin-
istration and medicines management is required to
support delivery of children’s healthcare in various com-
munity settings (eg home and school) [9].
The illness trajectories of many childhood conditions
now extend into adulthood [16]. There is little informa-
tion available for young people and their families around
transition between child and adult service provision,
with many young people seemingly unprepared to man-
age their own care and live independently [17]. Findings
from an overlapping SDO study looking at transition of
young people to adult services (TCADS) are expected
soon [18]. Available standard patient information is
often of poor quality and may not be easily accessible or
understandable for children, young people and their
families [1].
Policies need to be placed within the context of chil-
dren and young peoples’ lives, illnesses they experience
and what best suits their needs. Long-term conditions
such as diabetes are commonly treated with medicines
and children/young people increasingly take responsibil-
ity for their regimes over time, especially during school
hours [19]. Children and young people need to be
involved with their families/carers and professionals in
decision-making about their care-management, includ-
ing understanding risks and benefits, and specific
instructions to ensure optimum effect [9]. Research has
been aimed at identifying aspects of structured educa-
tion programmes, for example comparing their effective-
ness, [20] developing innovative curricula, [21] and
exploring acceptability to adolescents and their parents
and eliciting ideas on how they would set about design-
ing education sessions [22]. There is also work on psy-
cho-educational interventions [23].
Clinical guidelines indicate that high-quality, child-
centred information underpins the achievement of opti-
mal glycaemic control with the aim of minimising acute
re-admissions and reducing the risk of complications in
later life [24]. There is, however, insufficient evidence
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betes education and medicines management for children
and young people [25-27]. Likewise tailored, child-
centred information could equip children and young
people with the knowledge to become expert in diabetes
care [23,24].
Building on research evidence determining children
and young people’s preferred types and formats of infor-
mation across five tracer groups and associated critical
discourse analysis derived from the linked IMP qualita-
tive project, the pragmatic trial protocol reported here
aims to fulfil a significant gap in current knowledge con-
cerning children’s diabetes information and its use in
routine practice to promote optimal self-care and medi-
cines management [28].
Methods/Design
Research aims
The aim of the research is to develop and evaluate an
individually-tailored, age-appropriate diabetes diary and
information pack to support decision-making and self-
care relating to insulin management and electronic
blood glucose monitoring for children and young people
aged 6-18 yrs with type 1 diabetes, compared with avail-
able resources in routine clinical practice.
Objectives
To:
1. Review gold-standard clinical guidelines, currently
available information including findings from the linked
qualitative IMP study to identify best practice, and
types/formats of information most likely to assist age-
appropriate decision-making and choices concerning
blood glucose monitoring and insulin management.
2. Develop an age-appropriate information interven-
tion (child-centred diabetes diary and information pack)
for children and young people, to support appropriate
use of blood glucose meters to optimise management of
and concordance with their insulin regime.
3. Explore the utility of the child-centred diabetes
diary and information pack (in this context utility refers
to ease of use and fitness for purpose) within different
contexts in which children and young people manage
their routine diabetes care (home, school, community)
with and without support from parents or healthcare
professionals, and in alternative settings.
4. Explore how children/young people with and with-
out their parents, teachers, nurses, doctors use (or not)
the diabetes diary and information pack to support deci-
sion-making; in particular how children and parents
‘self-prescribe’ the correct (or incorrect) dose of insulin.
5. Identify similarities and differences between the dia-
betes diary and information pack developed for adoles-
cents and those available within adult diabetes services.
6. Evaluate the diabetes diaries and information pack
within the context of routine diabetes care in relation to
patient outcomes (diabetes-specific health-related quality
of life, generic health-related quality-of-life, medicine
and treatment concordance, acceptability, ease of use,
and glycaemic control).
7. Identify gaps in knowledge to inform a future
research agenda.
Design
To meet our objectives, which are aligned with the
phases of the MRC Framework for RCTs of complex
interventions, a four-stage study has been designed
[29,30].
Stages 1 and 2 to develop the information intervention
have mostly been completed and will be described
briefly. This protocol focuses on Stage 3, the rando-
mised controlled trial to evaluate the effectiveness and
cost effectiveness of the children and young people’s age
appropriate diabetes diaries and information packs
developed in stages 1 and 2.
The four stages are as follows:
Stage 1. Review and, where appropriate, undertake
further work to identify types/formats of information
most likely to assist age-appropriate decision-making/
choices related to children/young people with type 1
diabetes.
Stage 2. Construct age appropriate diabetes diaries and
information packs, and consult with children as
appropriate.
Stage 3. Conduct a pragmatic evaluation to assess uti-
lity, acceptability, effectiveness and cost effectiveness of
the diabetes diaries and information pack.
Stage 4. Undertake data synthesis and comparative
analysis of stages 1-3.
Conceptual and methodological frameworks
In addition to using the MRC Framework for designing
and evaluating complex interventions, the Promoting
Action on Research Implementation in Health Services
(PARIHS) framework will be used as the framework for
the translation of evidence into practice evaluation
[31,32]. The framework has been theoretically and
empirically developed to represent the interplay and
interdependence of the many factors influencing imple-
mentation of evidence into practice. This is explained by
a function of the relation between evidence, context and
facilitation [32-34]. The hypothesis offered is that for
implementation of evidence to be successful there needs
to be clarity about the nature of the evidence being
used, the quality of context, and, the type of facilitation
needed to ensure a successful process. The framework
has been used by others to inform the design and eva-
luation of evidence into practice initiatives [35-37].
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because:
1. It aims to introduce new diabetes diaries and
assembled information packs (evidence) into children’s
self-care regime and healthcare practice in order to
improve blood glucose meter use and insulin manage-
ment. Understanding the factors that influence its
implementation and use will be important in determin-
ing the acceptability and feasibility of the information
pack (facilitation)-this framework will provide a concep-
tual guide for mapping these issues.
2. Understanding how the information pack is used in
different contexts where children/young people manage
their diabetes will be key in the evaluation of its utility
and contribution. Applying the framework will allow a
focus on the key contextual variables mediating the
implementation and use of the information pack.
3. It facilitates the gathering of individual (e.g. child/
practitioner/carer) experiences as well as appreciating
the fit with the broader context of care delivery.
Plan of Investigation
Stage 1. Review of literature and discourse analysis of
currently available children’s health information
Literature review
We are undertaking an ongoing systematic review of lit-
erature, policy, evidence of cost-effectiveness, best prac-
tice clinical guidance and management plans that will
run throughout the study. We have used a scoping
review of current evidence from the IMP project to
inform intervention development and have extended the
focus on childhood diabetes diary and information pack
development.
Critical discourse analysis of currently available childhood-
diabetes information sources
We have used completed IMP project critical discourse
analysis findings to inform intervention development
and have focused in detail on childhood diabetes. We
have explored management of childhood diabetes and
focused on blood glucose monitoring and insulin man-
agement as a key exemplar concerning medicine man-
agement, self-care and concordance. We have also
looked specifically for similarities and differences in the
discourses and philosophies underpinning children’s/
young peoples’ and adult care pathways and manage-
ment plans to see how and in what ways medicine man-
agement and self-care discourses/philosophies change at
key stages across the lifespan. Information sources
across all mediums and sectors (eg. NHS, pharmaceuti-
cal) were sought. This work established what sources of
diabetes information were currently available to chil-
dren/young people and their families. We have also
identified the underlying assumptions of the information
sources and their main messages, and we have assessed
their applicability in terms of age, disability, ethnicity
and gender, and for those children living away from
their families. Analysis of the content has identified
whether key messages match clinical guidance on child-
hood diabetes management.
Stage 2. Diabetes diaries and information pack
development
Expert clinical advisory group
Towards the end of phase 1, we convened an expert
clinical group to discuss what gaps existed in current
children’s diabetes information, and what new informa-
tion could be produced within the study budget and
time constraints. It was decided that evidence concern-
ing preferred formats and presentation of age-appropri-
ate key health messages would be used to design and
develop a series of age-appropriate children’sd i a b e t e s
diaries that record daily insulin management and blood
glucose measurements, and carbohydrate counting
sheets. In addition, the diary would be central to an age-
appropriate information pack of existing diabetes and
diabetes-related information resources that were consid-
ered high quality in terms of content and identified by
children and young people in focus groups and inter-
views as being attractive and relevant to them in terms
of content and presentation.
Evidence from stage 1 (ongoing literature review and
discourse analysis) has been used as an empirical basis
for developing the age appropriate diabetes diaries and
information packs. The diabetes diaries and information
pack were designed in conjunction with children/young
people, parents, healthcare professionals, and a chil-
dren’s medical illustrator.
Qualitative interviews and focus groups
To establish the context for the development of the dia-
betes diaries and information packs and their imple-
mentation in routine practice, linked with the IMP
project, we have conducted 7 focus groups and 48 inter-
views to ascertain children and young people’sv i e w so f
currently available information resources across 5 tracer
conditions including diabetes, and explored children
and young people’s information needs related to mana-
ging their condition and self-care, including diabetes.
We also interviewed 52 parents and 11 healthcare pro-
fessionals and undertook non-participant observations
of routine clinical encounters where information is
exchanged.
O v e rt h ec o u r s eo ft h eE P I Cs t u d y ,w ep l a nt o
increase the number of interviews with children and
young people with type 1 diabetes to around 20, with
the specific aim of including those who live or have
lived away from their families in the short, medium or
long term (such as summer camp, school trips, foster or
institutional care etc) to ascertain children and young
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betes in various everyday contexts.
In addition, approximately 20 healthcare professionals
drawn from participating trial sites (approximately two
from each trial site), will be interviewed to document
current routine practice and local clinical care pathways
for children with type 1 diabetes in their sites.
Obtaining children and young people’s perspectives on
various iterations of the age appropriate diabetes diaries
and information packs
With permission from the organisers of family days run
by children’s diabetes charities and support groups, we
have asked for children and young people’s general
views on various iterations of the age appropriate dia-
betes diaries and information packs. They have com-
mented on artwork, colours, formats, sizes and types of
information. We have also used advertisements in char-
ity and Roche family support network news letters and
communications inviting children and young people to
visit the EPIC Project website. Having given their online
consent (and parent/guardian consent if under 16 years
of age) children and young people were invited to take
part in web-based activities such as choosing which
image they liked best out of a selection, and comment-
ing on various iterations of the information resources in
production.
Children’s diabetes information resources produced for the
trial
In an iterative approach, integrating findings from the
linked IMP Project, and building throughout stages 1 and
2, we have produced the following range of resources
that can be individually tailored for pragmatic evaluation
in routine clinical practice-stage 3:
￿ Three diabetes diaries for children and young peo-
ple using multiple insulin injections (6-10 years, 11-
15 years and 16-18 years);
￿ One diabetes diary (6-18 years) for children and
young people using insulin pumps;
￿ Child-friendly sheets for recording carbohydrate
intake;
￿ Three age-appropriate information packs contain-
ing published diabetes information bound in an age-
appropriate folder (6-10 years, 11-15 years and
16-18 years), and
￿ Stickers and pens for children and young people to
personalise their folder.
Stage 3. Trial platform to evaluate the diabetes diaries
and information packs in routine practice
Methods
Study design This trial is an individually randomised
controlled trial with two parallel groups. The protocol is
summarised in Figure 1.
Main hypothesis Children and young people with type
1 diabetes aged from 6-18 years, receiving and using an
individually-tailored and age appropriate diabetes diary
and information pack will increase their diabetes-related
self-efficacy and quality of life at 6 months.
Secondary hypotheses That receiving and using an indi-
vidually-tailored and age-appropriate diabetes diary and
information pack will lead to an improvement in
HbA1c, generic health-related quality of life, and a
range of care process outcomes, and be cost-effective.
Setting NHS children’s, transition, and young adult dia-
betes clinics, and a range of domestic/community set-
tings (eg family homes and schools).
Site selection and preparation Depending on the size
of site and number of children/young people with dia-
b e t e st y p e1 ,w ee n v i s a g eu pt o1 0s i t e s( d e p e n d i n go n
current NHS re-organisation and amalgamation of
Trusts) will recruit children and young people. We will
be guided by co-applicant clinicians and the MCRN/
CRC Cymru research network who have an overall view
of available of sites for trials and will have an overall
s t r a t e g i cr o l ei ns u p p o r t i n g research teams to facilitate
site and participant recruitment [38].
The age-appropriate diabetes diaries and information
pack will be individually-tailored and introduced by
nurses/doctors in children and young people’sd i a b e t e s
clinics during routine visits. We will hold a launch event
to familiarise healthcare professionals with the informa-
tion pack in each participating site.
Types of participants
Inclusion criteria
Children age 6-18 years with type 1 diabetes.
Exclusion Criteria
Children/young people with:
1. Needle phobia;
2. Any significant social or emotional problems where
such problems in the opinion of the clinical team are
likely to impair a child’s ability to take part in the trial;
3. Any significant physical or intellectual impairment
which in the opinion of the clinical team is likely to
impair a child’s ability to take part in the trial, and
4. An inability to communicate in an age appropriate
way in written and spoken English.
The underlying principle guiding clinicians is that
children/young people should be entered into the trial
where at all possible and should only be excluded if
being in the trial would be detrimental to their social,
emotional or physical health, or children/young people
or their parents are unwilling to give their informed
consent/assent.
Sample size calculation and effect size
A systematic review provides sample size calculations
for studies of educational interventions targeting
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children with diabetes [39]. They calculated a total of
130 randomized subjects in order to detect a 0.5 (med-
ium) psychological effect size, with a power of 80% at
the 0.05 significance level (assuming equal assignment
in the two arms). They report that the effect size for
psychological outcomes is more predictable with a med-
ian and mean of 0.38 and 0.35 respectively, therefore we
will aim to detect an effect size of 0.4.
The sample size is 252 children/young people with
type 1 diabetes (this is allowing for a 10% drop out rate,
and adjusting for a 2:1 randomisation strategy). In order
to gain more experience of the new intervention in rou-
tine practice, we will employ a 2:1 randomization strat-
egy and randomise 168 children/young people into the
intervention arm and 84 children/young people into the
non intervention arm, stratified by age, gender and
length of time since diagnosis (<2 years and >2years).
Figure 1 shows the flow of patients through the trial.
Recruitment Where appropriate consultants, nurses, or
MCRN/CRC Cymru research nurses will send an infor-
mation pack to a child/young person (and if under 16
years their parent/guardian) attending a clinic one week
prior to the clinical appointment. During the clinic visit,
the consultant/nurse/research nurse will ask them if
they want to take part in the study. If the child/young
person agrees to take part in the study, the consultant/
nurse/research nurse will take the consent from young
people over 16 years, assent and parent/guardian proxy
consent from children under 16 years. Children and
Figure 1 Flow of patients through the trial.
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dard care.
Allocation Children age 6-18 years fulfilling the inclu-
sion criteria and for whom appropriate consent(s)
(proxy if appropriate) are obtained will be randomized
using an independent web based randomisation service
supported by the North Wales Organisation for Rando-
mised Controlled Trials in Health and Social Care
(NWORTH).
Randomisation A web-based, password protected,
secure adaptive randomisation with a telephone backup
has been developed.
168 children/young peoplew i l lb er a n d o m i z e di n t o
the intervention arm and 84 children/young people into
the no intervention arm, stratified by gender, length of
time since diagnosis (<2 years and >2 years) and age
(stratification by age will be into the following age cate-
gories: 6-10 years; 11-15 years; and 16-18 years).
Planned interventions
Group 1 - Information intervention An age-appropri-
ate diabetes diary and information pack produced or
assembled for the study will be selected and individu-
ally-tailored as appropriate to each child/young person
depending on their age and diabetes management, and
introduced by nurses/doctors and as appropriate other
multi-disciplinary team members in clinic during rou-
tine visits by children/young people between the ages of
6-18 years with type 1 diabetes. Parents of children
under 16 years will be provided with verbal and written
guidance on supporting their child’s use of the informa-
tion pack. Parents attending clinic consultations with
young people over 16 years will receive the same verbal
advice as the young person, and written guidance will
be aimed at the young person.
Group 2-Standard practice Children age 6-18 years with
type 1 diabetes receiving standard practice will be the
‘practice as usual’ control group. A manual of standard
practice for each centre will be produced. This will help
with the comparisons of outcomes at the end of the trial.
Outcome measures
Primary outcome measures Choice of outcomes is
guided by a Health Technology Assessment commis-
sioned systematic review recommending that HbA1c
(glycaemic control measure) is not the appropriate pri-
mary outcome on which to assess benefits of an inter-
vention designed to more directly effect behaviour/self-
management [39]. Therefore, the primary outcome mea-
sure is diabetes self-efficacy and quality-of-life as mea-
sured by the single composite score derived from the
Diabetes PedsQL.
Secondary outcome measures Secondary outcomes
include: HbA1c, generic quality of life, routinely col-
lected NHS/child-held data, costs, service use, accept-
ability/utility.
Baseline, 3 and 6 month data collection
Children/young people (if appropriate with support of,
or proxy report by parents) will complete a baseline
questionnaire recording sociodemographic variables,
patient characteristics, and PedsQL (generic, diabetes
and parent versions). The EQ-5D will be completed by
parents (as a proxy measure) as well as the child/young
person.
Follow-up questionnaires, containing the same out-
come measures as at baseline, and with an additional
focus on process will be administered at 3 months and
6 months, (including data on health service use, epi-
sodes of diabetic ketoacidosis, and all hospital admis-
sions for acute complications). Non-responders will
receive telephone/postal reminders after two and four
weeks.
Baseline and subsequent HbA1c measurements and
routinely collected NHS/child-held data will be collected
by the clinicians/diabetes nurse specialists/MCRN
nurses, or researchers where appropriate. Blood glucose
meters will be checked for the previous 250 blood glu-
cose records if considered appropriate by the clinician
and if used as part of routine clinical practice.
Implementation, service utilisation and costs
Economic Evaluation
Murphy et al., strongly recom m e n dt h a tc o s t - e f f e c t i v e -
ness is considered as an outcome as none of the studies
in their review of psycho-educational interventions with
adolescents addressed it [39]. We will therefore weigh
up the diabetes related costs and consequences of the
different interventions (that i n v o l v er e s o u r c eu s e )f r o m
an NHS perspective. Contacts with NHS services and
resource use will be collected via questionnaire. Costs
will be obtained from national sources. Activity will be
collected for 6 months.
Process evaluation
Following the intervention, sixty children/young people
and parents (as appropriate) will be interviewed by tele-
phone or in person (40 from the intervention group and
20 from the control group) in order to gain further
understanding about implementation issues, and user
experiences of the intervention diabetes diaries and
information packs or resources used in existing routine
practice.
Healthcare professionals associated with the care of
children/young people recruited to the trial will also be
invited to complete a semi-structured questionnaire to
determine acceptability and impact of the new diabetes
diaries and information pack in practice.
Data handling
SPSS® and Atlas Ti® will be used for statistical, qualitative
and healthcare professional questionnaire data handling
[40,41]. NWORTH will support data management and
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tronic data collection system (TrialSys® ) in each centre
with an alternative paper-based system [42]. Data will
be transmitted securely electronically to the clinical
trials unit NWORTH [43].
Data analysis
Statistical analysis Initial descriptive statistics will
describe characteristics and demographics of the sample
at baseline. We shall compare outcomes between the
two groups by analysis of covariance to adjust for possi-
ble differences in baseline measurements. This will be
repeated at 3 and 6 months comparing intervention and
control groups. In addition, longitudinal analysis will
consider any changes over time. These analyses will
examine changes in the quality of life measures (paedia-
tric EQ-5D, PedsQL generic and diabetes-specific health
measures) over baseline, both using a pairwise compari-
son, studying change on individuals, and a cohort analy-
sis comparing overall change in group means.
Multiple regression analyses will be performed to
identify factors which predict good outcomes within and
between groups.
Cost effectiveness analysis
We will undertake a cost-utility analysis, whereby costs
are in monetary terms and outcomes are in preference-
based non-monetary units such as Quality Adjusted Life
Years (QALYs). The area under the curve method will
be used for calculating QALYs weighting survival by
quality of life weights measured using the paediatric
EQ-5D instrument. We will compare our findings with
the unofficial NICE ceiling of £30,000 per QALY. Dis-
counting will not be necessary given the time period.
Uncertainty
The bootstrap calculation is a useful statistical approach
for examining the uncertainty in cost-effectiveness analy-
sis. It is a non-parametric simulation method used when
the underlying data has a skewed distribution. The boot-
strap method can be used to provide an estimate of the
probability distribution of the cost-effectiveness ratio, its
confidence interval, or variance in the ratio.
Qualitative data analysis
Interviews will be tape recorded and transcribed. The
process analysis accompanying the subsequent evaluation
will explore implementation issues and compare the
experience of managing diabetes and insulin manage-
ment and self-care processes between the intervention
and control pathways. The predominantly deductive ‘fra-
mework approach’ will be used to categorise qualitative
data based on the literature, conceptual framework, the
trial design, and the evaluation focus [44].
Healthcare professional questionnaires
Healthcare professionals’ questionnaire data will be ana-
lysed using descriptive statistics and open ended questions
will be subject to content analysis.
Stage 4. Data synthesis and comparative analysis
Data from stages 1 to 3 will be synthesised and subject
to comparative analysis.
Ethical arrangements
Ethical approval A favourable opinion has been
received from Cardiff Research Ethics Committee. Refer-
ence 08/MRE09/57
Risks and anticipated benefits for trial participants
The research carries minimal risk and therefore it is
considered appropriate to involve children and young
people in evaluating the diabetes diaries and information
packs [45].
We have convened an expert clinical advisory group
and developed a specific clinical governance and risk
management framework with diabetes clinicians to qual-
ity assure and ‘sign off’ children’s diabetes information
produced for the study as appropriate for use in the
NHS (see Figure 2).
Team members with direct contact with children will
undergo appropriate Child Safeguarding screening, and
follow local child safeguarding procedures in each site.
Consent for participation in the trial Participants will
be children/young people between the ages of 6 to 18
years. Young people over the age of 16 can provide their
own consent, however consent by proxy (from a parent
or guardian) will be obtained for children under the age
of 16 years. Assent will be sought from children under
16 years.
Discussion
The multi-disciplinary team and innovative design will
ensure that children’s needs are made explicit within
policy implementation and service delivery, providing
generalisable evidence to: 1. Identify types/formats of
information to underpin structured education pro-
grammes for children with type 1 diabetes. 2. Guide
integration of high quality children’s information needs
w i t h i ns e r v i c ed e l i v e r yt of a c i l i t a t ec h o i c ei nr o u t i n e
clinical practice at national and local levels. 3. Inform
decisions about the allocation of NHS resources in rela-
tion to service use. 4. Assist the development of a future
research agenda related to age appropriate, child-centred
information across a range of conditions, in order to fill
an identified service delivery and organisation gap.
We have also successfully integrated high levels of
participation with children, young people, families and
healthcare professionals in the study at various key
stages. The study will undoubtedly also yield further
useful and valuable evidence on process and outcome
measurement generally in a range of children and young
people that can be used to inform the design of future
trials of information and behavioural interventions gen-
erally across a range of tracer conditions. Evidence that
addresses the preparation of children in order to
Noyes et al. BMC Pediatrics 2010, 10:70
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adulthood is critical to the NHS agenda
The study complements other children’s diabetes stu-
dies undertaken by team members and findings will
contribute to a developing a wider evidence base with
specific reference to children/young people with type 1
diabetes [14,18,46].
We have been asked by NIHR SDO to publish the
trial management and research governance framework
developed for EPIC.
Trial management and research governance framework
Team management
Drawing on team members’ experiences of managing
teams, we have adapted a template shared by PB and
constructed a management and research governance fra-
mework to support the four phases of our study (1. con-
text: review literature and current information 2.
develop information pack, 3. randomized controlled
trial, 4. synthesis of phases 1-3 and comparative analy-
sis), and to ensure cohesive and effective working
between team members (see Figure 2).
Key Groups
Group tasked with overall responsibility and governance:
‘Governance and Management Group’
Management and research governance is being over-
seen by a group composed of the co-applicants named
on the bid, led by AW and JN. Co-applicants were cho-
sen to support this application on the basis that they
each have established reputations in fields and expertise
most relevant to the proposed research, including: sys-
tematic review skills, research skills, trials expertise,
experience of user groups/working with users, clinical
expertise, policy knowledge, services planning and devel-
opment, management and delivery, multi-agency/disci-
plinary partnerships, networking and dissemination
skills. In addition, co-applicants have specialist roles
within relevant clinical research thematic networks (PB,
JG, JN) and professional bodies (JG, CJ, ML, JN, AW).
All co-applicants are experienced and effective com-
municators in their capacity as researchers, clinicians
and managers. The majority of us have collaborated pre-
viously or are currently collaborating on other projects.
While we each bring different discipline and profes-
sional perspectives to bear on the objectives we have
set, we aim to promote team values with an inclusive
approach where differing opinions are respected. Many
of us have developed considerable confidence as team
leaders in multi-disciplinary/multi-agency settings. The
Governance and Management Group will normally meet
once a year, and will report to the funder. Additionally,
teleconference meetings will be called if required.
Group tasked with day-to-day management: Opera-
tional Management Group
Day-to-day management of operational aspects of the
programme will be the responsibility of the two PIs
working with the two RAs employed for the duration of
the study. AW will work with one RA based in Cardiff,
meeting face-to-face on a weekly basis and JN with one
RA based in Bangor, also meeting face-to-face weekly.
This core group of four researchers will be in close con-
tact with each other via a secure web site and will com-
municate via teleconference or telephone at least every
2 weeks during the 36 months of the programme. They
will meet face to face in the early stages to establish
working relationships. Our experience suggests this
Figure 2 Trial governance and management arrangements.
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in contact with members of the Working Groups, Gov-
ernance and Management Group and Advisory Group
as detailed in the section ‘Working together effectively’
below. Management of information will be critical to
the day-to-day management of the study; common data
bases and resources have been set up and it has been
important to identify precise division of labour from
outset of study.
Working together effectively
Based on previous experience and current models of
good practice employed on projects by the co-applicants,
we have set up Working Groups. These will give clarity
to the roles and responsibilities of the co-applicants who
have been costed into the price of the proposed research.
They are planned to provide particular advice and gui-
dance to the PIs and RAs in each phase of the study: 1.
Context: review of literature and current information 2.
Development of the information pack, 3. Randomized
controlled trial, 4. Synthesis of phases 1-3 and compara-
tive analysis. Guidance will be related to varying aspects
such as range of policy, best clinical practice, child/user-
friendly construction of question sheets and so on.
Guidance on dissemination of findings will be a key
aspect of their role. Individual members of the Govern-
ance and Management Group are leading activity in the
working groups, working closely with the Operational
Management Group. Advisory Group members will be
called on for specific expertise, including dissemination
skills. Each working group reports to the Governance
and Management Group via the Operational Manage-
ment Group.
Trial Management
The North Wales Organisation for Randomized Trials in
Health and Social Care (NWORTH) will support imple-
mentation and running of the trial.
Working group three in Figure 2 has been convened as a
Trial Management Group, Chaired by LL (co-applicant)
that meets monthly by teleconference. Membership
includes PIs, ROs, trial statistician, and health economists.
Trial Steering Group
A trial steering group (TSG) has been convened under
the independent Chairmanship of Professor Tim Barrett.
The TSG includes clinical, academic, parent and young
person representation and will meet every six months in
person and every six months by telephone conference.
Data Monitoring and Ethics Committee
An independent data monitoring and ethics committee
(DMEC) has been convened and chaired by Dr Chris
Foy (independent statistician), who will report to Profes-
sor Tim Barrett (Chair TSG). The DMEC will meet face
to face every six months and virtually every six months
prior to the TSG meeting.
Serious Adverse Event Reporting
A serious adverse event monitoring and reporting sys-
tem has been devised in conjunction with NWORTH.
MCRN and CRC Cymru
The study has been adopted and supported locally by
MCRN, Diabetes Research Network, and Children and
Young Peoples’ Network CRC Cymru.
Additional Stakeholder and lay input
In addition to the clinical expert advisory group
described previously, we wish to involve at various
stages of the study those people we have already con-
sulted in preparing the research proposal-parents, chil-
dren, young people-and others such as clinicians,
managers and voluntary sector representatives. A num-
ber are working with us on the linked IMP project.
Additional stakeholder and lay advice and input will
t h e r e f o r eb ed r a w nf r o mp e o p l ew i t hk n o w l e d g ea n d
experience relevant to the aims of the project. Previous
experience of this type of research by the co-applicants
suggests that collaboration, communication and trans-
parency with key stakeholders from the outset will be
crucial to the success of the proposed study.
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